Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Core Viewpoint - Myriad Genetics has received a second patent for its tumor-informed, high-definition molecular residual disease (MRD) assay, enhancing its market position in precision medicine [1][3]. Patent Developments - The newly issued U.S. patent no. 12,024,749, titled "Combinatorial DNA Screening," focuses on Myriad's MRD technology, which detects circulating tumor DNA in patient fluid samples [1][2]. - Earlier this year, Myriad received a complementary patent for methods of preparing cell-free DNA, which also supports high sensitivity tumor-informed MRD assays [2]. Technology and Market Position - The combination of these patents positions Myriad to establish a proprietary MRD assay capable of detecting tumor DNA at lower levels than competitors, utilizing genome-scale sequencing technology [2]. - The company aims to leverage its existing technology and infrastructure to commercialize the Precise MRD assay, enhancing oncology care for patients [3]. Ongoing Research and Collaborations - Myriad is actively developing the Precise MRD assay through high-impact studies and collaborations with notable institutions, including Memorial Sloan Kettering and The University of Texas MD Anderson Cancer Center [3][4]. - Preliminary results from these collaborations are anticipated to be released in the fall [3]. Company Overview - Myriad Genetics is a leader in genetic testing and precision medicine, focusing on advancing health through genetic insights that improve patient care and reduce healthcare costs [5].